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Chronic beryllium disease is predominantly a pulmonary granulomatosis that was originally
described in 1946. Symptoms usually include dyspnea and cough. Fever, anorexia, and
weight loss are common. Skin lesions are the most common extrathoracic manifestation.
Granulomatous hepatitis, hypercalcemia, and kidney stones can also occur. Radiographic and
physiologic abnormalities are similar to those in sarcoidosis. While traditionally the pathologic
changes included granulomas and cellular interstitial changes, the hallmark of the disease today is
the well-formed granuloma. Immunologic studies have demonstrated a cell-mediated response to
beryllium that is due to an accumulation of CD4+ T cells at the site of disease activity. Diagnosis
depends on the demonstration of pathologic changes (i.e., granuloma) and evidence that the
granuloma was caused by a hypersensitivity to beryllium (i.e., positive lung proliferative response
to beryllium). Using these criteria, the diagnosis of chronic beryllium disease can now be made
before the onset of clinical symptoms. Whether, with early diagnosis, the natural course of this
condition will be the same as when it was traditionally diagnosed is not known. Currently,
corticosteroids are used to treat patients with significant symptoms or evidence of progressive
disease. Environ Health Perspect 104(Suppl 5):945-947 (1996)
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Chronic beryllium disease (CBD), first
described in 1946, is a disease of the 20th
century. Hardy and Tabershaw described
17 cases in the fluorescent lamp industry, in
which symptoms developed 6 months after
initial exposure to beryllium (1). Many
patients had far advanced disease as evi-
denced by their severe symptoms. Anorexia
was present in all 17, 16 had weight loss, 15
had dyspnea on exertion, and 13 com-
plained ofcough. On physical examination,
rales were present in 13, tachycardia in 10,
fever in 9, cyanosis in 5, edema in 5, and
clubbing in 2. As expected for the initial
description of a syndrome, patients were
identified only ifsevere disease was present.
The delayed onset and persistent nature
of this condition were contrasted to a
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previously described complication ofberyl-
lium exposure, acute beryllium disease (2).
Acute beryllium disease was only seen after
intense exposure to beryllium and was
thought to be an acute chemical burn. This
latter condition is largely ofhistorical inter-
est and would occur today only if there
were a plant explosion.
To collect all possible cases ofberyllium
disease, a case registry was developed. Six
criteria were developed for entering cases
into the registry, two based on document-
ing exposure and four based on evidence of
a chronic pulmonary process. For an indi-
vidual to be entered into the beryllium reg-
istry, four of the six criteria had to be
satisfied and the patient had to have a his-
tory ofexposure or elevated tissue levels of
beryllium. Workers at risk for beryllium
exposure were production and mainte-
nance workers in beryllium extraction;
basic beryllium plants producing metallic
beryllium, beryllium alloys, or beryllium
oxide powder; foundries melting beryllium
alloys; beryllium machine shops; and
plants processing beryllium oxide powder.
Operations that put workers at risk
included grinding, lapping, or abrading
beryllium-containing materials; welding,
brazing, or melting such materials; BeO-
furnace cleaning or rebuilding; laser
cutting, scribing, or trimming; dental labo-
ratory operations; BeO extrusion or press-
ing; heat treatment ofberyllium alloys; and
chemical milling ofberyllium. Evidence of
a chronic pulmonary disease was based
on clinical symptoms, chest radiographs,
pulmonary function tests, or pathology.
The clinical symptoms usually reflect a
chronic pulmonary disease process (3).
Thus, cough and shortness of breath are
usually present. However, nonspecific
symptoms such as fever, anorexia, and
weight loss may also be present. In addi-
tion, granulomatous skin lesions may be
seen in some patients. Hypercalcemia and
kidney stones also have been reported.
While granulomatous hepatitis has been
described, it is rarely symptomatic. Radio-
logic abnormalities are usually similar to
those observed in sarcoidosis (4). These
include fibronodular changes that usually
involve the upper lobe. Hilar and mediasti-
nal adenopathy are present in about 50%
of patients but frequently the nodes are
small. Large, potato-sized nodes that can
be seen in sarcoidosis have not been
described in chronic beryllium disease.
Thin-section computed tomographic fea-
tures of chronic beryllium disease have
been compared to chest radiographs (5).
While abnormalities were detected in 10 of
13 patients with normal chest radiographs
and biopsy-proven disease, the abnormali-
ties detected-parenchymal nodules and
septal lines-are not specific for chronic
beryllium disease.
The typical pulmonary function abnor-
malities observed in chronic beryllium dis-
ease are those that have been associated
with other interstitial lung disorders. These
include a decrease in the vital capacity and
the total lung capacity (i.e., a restrictive
pattern) and a reduction in the diffusing
capacity (6). While obstructive changes
also have been observed, these changes
tend to occur late in the disease (7).
The classic pathologic changes that
have been described in CBD were described
in a review of 130 cases from the beryllium
case registry (8). The majority (80%) of
the patients had evidence ofmarked cellu-
lar interstitial changes. Over half of these
patients had poorly formed or no granu-
loma formation. The remaining patients
who had marked cellular interstitial
changes had prominent and well-developed
granuloma formation. Twenty percent of
patients had little evidence ofcellular inter-
stitial changes but did have numerous and
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well-formed granulomas. In contrast to this
study, most patients who appear to have
been diagnosed in the 1980s showed evi-
dence ofgranuloma formation (6,9,10).
The difference between this earlier study
and current studies may be the lower envi-
ronmental exposure that has occurred in
industry in the last 20 years. Today, the
well-developed granuloma is considered
the classic pathologic change in CBD.
These granulomas are indistinguishable
from those present in sarcoidosis. While
beryllium can be detected within granu-
lomas by specialized techniques, these
techniques are not readily available (11).
As the role of immunologic mecha-
nisms in CBD have become clearer,
immunologic tests ofberyllium hypersensi-
tivity have played an increasing role in
diagnosis of the disease (12). Initially,
beryllium hypersensitivity was determined
by patch testing (13). However, because of
fears of sensitization and untoward reac-
tions, testing ofberyllium hypersensitivity
did not become practical until the 1970s
when in vitro blood lymphocyte prolifera-
tion tests were developed (14,15). These
tests were used to confirm a history of
beryllium exposure and sometimes (mistak-
enly) used to exclude a diagnosis ofberyl-
lium disease. In the 1980s, lymphocyte
proliferation testing was applied to cells
obtained by bronchoalveolar lavage (BAL)
(6,9,10,16-19). These tests confirmed not
only the ability ofberyllium to stimulate a
cell-mediated hypersensitivity reaction, but
also the accumulation of beryllium-sensi-
tive CD4+ T lymphocytes (6,18) at the site
ofdisease activity.
Based on these and other studies, the
pathogenesis ofCBD is thought to involve
the following processes: First, airborne
beryllium is inhaled and deposited in the
airspaces in the lung. Because beryllium is
poorly excreted from the lungs, this beryl-
lium will persist for a prolonged period
(20). After an unknown period, certain
individuals will become sensitive to beryl-
lium. Beryllium, acting as a hapten, binds
proteins/peptides in the lung and elicits a
proliferation of CD4+ T lymphocytes
(6,18). These sensitized lymphocytes
secrete a variety of cytokines that are
responsible for the recruitment, activation,
and maturation ofmacrophages into epit-
helioid cells. Epithelioid cell granulomas
form and lead to fibrosis and destruction of
normal lung parenchyma.
Based on these immunologic findings, a
new gold standard for the diagnosis of
CBD was proposed (21), based on patho-
logic evidence of granulomatous disease
and beryllium hypersensitivity ofbroncho-
alveolar cells. The gold standard included
histologic evidence ofgranuloma, immuno-
logic evidence that granuloma was caused
by beryllium hypersensitivity, and a posi-
tive proliferative response ofbronchoalveo-
lar cells to beryllium. Other criteria, though
not considered a gold standard, were
strongly suggestive. These involved studies
consistent with pulmonary granulomas,
including radiologic (upper lobe nodular
densities ± adenopathy) and physiologic
(restrictive process or abnormal DLco)
studies. Equally suggestive studies consis-
tent with beryllium hypersensitivity or
exposure were those involving positive
blood proliferative response to beryllium
and localization of beryllium within the
granuloma. Using these new criteria, a
specific diagnosis ofchronic beryllium dis-
ease could be determined. There are several
important implications to the use ofthese
new criteria. First, a history of beryllium
exposure is not required to make a diagno-
sis ofchronic beryllium disease. Since there
have not been any descriptions ofindividu-
als who have bronchoalveolar lymphocytes
that react to beryllium and do not have a
history ofexposure to beryllium, the impli-
cation is that if an individual has bron-
choalveolar lymphocytes that respond to it,
that individual must have had some expo-
sure to beryllium. The challenge, then, is
to determine how the exposure occurred.
The second implication ofthese gold-stan-
dard criteria is that a patient need not have
clinical symptoms, radiographic abnormal-
ities, or abnormalities on pulmonary func-
tion testing to be diagnosed with CBD.
Thus, the diagnosis can be made earlier
than was previously possible. Whether,
with early diagnosis, the natural course of
this condition will be the same as when it
was traditionally diagnosed is not known.
Finally, the use of the proliferation test as
part ofthe diagnostic criteria for CBD sug-
gests that blood proliferation testing for
beryllium hypersensitivity might be a use-
ful means for early detection. Large-scale
studies are currently in progress since ini-
tial surveys (9,10) indicated that screening
workers with a blood proliferation test will
identify those with early disease that would
not have been detected otherwise.
In contrast to most occupationally
related lung disease, the early detection of
chronic beryllium disease is useful since
treatment of this condition can lead not
only to regression of the signs and symp-
toms, but also should prevent further pro-
gression ofthe disease. The management of
CBD is based on the hypothesis that sup-
pression of the hypersensitivity reaction
(i.e., granulomatous process) will prevent
the development offibrosis. However, once
fibrosis has developed, therapy cannot
reverse the damage. There have been no
controlled studies to determine the optimal
treatment for this condition. We currently
follow patients with yearly history and
physical examinations, chest radiographs,
pulmonary function tests, and exercise
physiology until there is definite evidence
that the beryllium hypersensitivity is begin-
ning to cause damage. Patients with evi-
dence ofearlylung damage are treated with
40 mg ofprednisone on alternate days for
6 months. Prednisone is tapered by no
more than 10 mg every other month until
there is evidence ofrenewed disease activ-
ity. Disease activity is monitored by the
same tests that demonstrated deterioration.
The lowest dose ofprednisone that prevents
disease is maintained. Whether individuals
require a lifetime of treatment remains
uncertain. However, animal studies (20)
suggest that once beryllium is deposited in
the lungs, the clearance is very slow. Thus,
with a persistent stimulus, it is likely that
prolonged corticosteroid therapy will
be needed.
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